导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 13.43% | 687/4766 |
| 近一周 | -1.83% | 2960/5456 |
| 近一月 | -3.50% | 2562/5412 |
| 近一季 | -1.43% | 1208/5222 |
| 近半年 | 5.44% | 792/4911 |
| 近一年 | 18.65% | 625/4391 |
| 近两年 | 82.58% | 811/2953 |
| 近三年 | 51.26% | 538/2252 |
| 成立以来 | 159.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.65% 874/4961 |
18.86% 1341/5312 |
- - |
- - |
| 2025 | 31.31% 1251/4813 |
3.62% 1062/3635 |
3.13% 1144/4076 |
23.38% 1546/4524 |
-0.41% 2489/4813 |
| 2024 | 7.75% 1624/3463 |
-0.19% 1081/2808 |
-2.19% 1149/3014 |
12.14% 2409/3129 |
-1.57% 1752/3463 |
| 2023 | -9.62% 1203/2656 |
5.31% 801/2280 |
-2.74% 643/2385 |
-6.13% 1436/2515 |
-6.00% 1589/2655 |
| 2022 | -16.69% 504/2207 |
-10.36% 394/1919 |
6.41% 703/2016 |
-12.52% 719/2113 |
-0.17% 1570/2208 |
| 2021 | 21.76% 159/1822 |
0.62% 281/1255 |
11.39% 378/1330 |
6.15% 241/1466 |
2.34% 618/1822 |
| 2020 | 34.42% 439/1250 |
-3.93% 330/1028 |
18.60% 330/1067 |
13.39% 322/1164 |
4.05% 876/1184 |
| 2019 | 49.66% 104/1092 |
32.77% 162/739 |
-2.80% 359/788 |
5.66% 138/850 |
9.75% 199/918 |
| 2018 | -24.84% 333/834 |
- - |
-8.35% 211/631 |
-5.65% 374/660 |
-13.31% 529/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 申万菱信中证500指数优选增强A VS. 长安沪深300非周期A(740101) |